Staphylococcal protein A - Protalex

Drug Profile

Staphylococcal protein A - Protalex

Alternative Names: PRTX-001; PRTX-100; SPA - Protalex

Latest Information Update: 19 May 2016

Price : $50

At a glance

  • Originator Protalex
  • Class Antirheumatics; Bacterial proteins
  • Mechanism of Action B cell inhibitors; Macrophage inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immune thrombocytopenic purpura
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Immune thrombocytopenic purpura; Rheumatoid arthritis
  • Phase I Autoimmune disorders

Most Recent Events

  • 25 Apr 2016 Interim efficacy and adverse event data from a phase I/II trial in Rheumatoid arthritis released by Protalex
  • 01 Apr 2016 Protalex completes the phase I/II SPARTA-II trial in Rheumatoid arthritis in USA (NCT02330445)
  • 11 Nov 2015 Staphylococcal protein A receives orphan drug status for Immune thrombocytopenic purpura in Europe before November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top